The company's high P/S ratio and decreasing revenues do not ...
The company's high P/S ratio and decreasing revenues do not match, causing concerns for investors. Unless the recent medium-term conditions improve significantly, investors may find it difficult to perceive the share price as fair value.
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Popularity With Investors Is Under Threat From Overpricing
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment